Company Filing History:
1 out of 17 
1 out of 4,455 
Years Active: 2025
Title: Nguyen Tan - Innovator in CAR T Cell Therapy
Introduction
Nguyen Tan is a prominent inventor based in Berkeley, CA, known for his significant contributions to the field of immunotherapy. He holds a patent for a novel approach to cancer treatment through the development of a protease-activating CD45-gate chimeric antigen receptor (CAR). This innovative technology aims to enhance the efficacy of CAR T cell therapy, providing new hope for patients battling various forms of cancer.
Latest Patents
Nguyen Tan's patent, titled "Protease-activating CD45-gate CAR," describes a reversibly gated effector polypeptide. This invention comprises an extracellular CD45 recruiting domain, a protease-cleavable linker, and a polypeptide that includes an extracellular ligand binding domain, a transmembrane domain, and an intracellular domain. The patent also covers nucleic acids, including vectors and expression vectors that encode the protease-activating CD45-gate CAR. Furthermore, it details methods of treatment for various conditions, particularly cancer, by administering immune cells such as T cells that express the CAR. The unique feature of this invention is that the CD45 gate inhibits activation of the CAR when it binds to an antigen, but this inhibition can be diminished when exposed to a specific protease.
Career Highlights
Throughout his career, Nguyen Tan has worked with leading companies in the biotechnology sector. He has been associated with Allogene Therapeutics, Inc. and Pfizer Corporation, where he has contributed to groundbreaking research and development in immunotherapy. His work has been instrumental in advancing the understanding and application of CAR T cell therapies.
Collaborations
Nguyen Tan has collaborated with notable colleagues in the field, including Shanshan Lang and Thomas John Van Blarcom. These partnerships have fostered innovation and have been crucial in the development of his patented technologies.
Conclusion
Nguyen Tan's contributions to the field of immunotherapy, particularly through his patented protease-activating CD45-gate CAR, represent a significant advancement in cancer treatment. His work continues to inspire and pave the way for future innovations in the fight against cancer.